Evidence map›Paper›PMID 20539226›Full record

ReviewCurrent opinion in nephrology and hypertension2010

Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Volker Vallon, Kumar Sharma

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in nephrology and hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Journal of diabetes and metabolic disorders · 2022
    Article
  5. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2022
    Article
  6. Review
  7. Review
  8. Review
  9. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017
    Article
  10. Review
  11. Review
  12. Early diabetic nephropathy in type 1 diabetes: new insights.Current opinion in endocrinology, diabetes, and obesity · 2014
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Aquaporin 11 insufficiency modulates kidney susceptibility to oxidative stress.American journal of physiology. Renal physiology · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Volker VallonDivision of Nephrology and Hypertension, Department of Medicine, University of California San Diego/Veterans Affairs San Diego Healthcare System, San Diego, USA.
Kumar Sharma
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Role and Mechanisms of Epithelial Injury in Diabetic NephropathyU01DK060995 · NIDDK · YESHIVA UNIVERSITY · PI BOTTINGER, ERWIN P. · 2001 to 2010
$6.0M
GLOMERULAR AND TUBULAR FUNCTION IN THE DIABETIC KIDNEYR01DK056248 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI THOMSON, SCOTT CULVER · 1999 to 2014
$4.6M
AUTOREGULATION OF GLOMERULAR FILTRATION RATER01DK028602 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI BLANTZ, ROLAND C · 1986 to 2011
$3.9M
TGF-b signaling in diabetic kidney diseaseR01DK053867 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHARMA, KUMAR · 1999 to 2009
$2.5M
NIDDK NIH HHS DK28602NIDDK NIH HHS DK56248NIDDK NIH HHS P30 DK079337NIDDK NIH HHS P30DK079337NIDDK NIH HHS R01 DK028602NIDDK NIH HHS R01 DK 053867NIDDK NIH HHS R01 DK053867NIDDK NIH HHS R01 DK056248NIDDK NIH HHS U01 DK 060995NIDDK NIH HHS U01 DK060995
6 · The paper itself

Abstract

purpose of reviewCurrent options for glycemic control are less than optimal in terms of efficacy and to reduce complications in the diabetic population. Selective inhibition of SGLT2 in the proximal tubule increases urinary glucose excretion thereby reducing plasma glucose levels, which may present a novel therapeutic approach. RECENT

findingsSGLT2 inhibitors enhance glucose excretion and improve glycemic control in patients with type 2 diabetes in the absence of clinically relevant hypoglycemia or sustained changes in volume status or glomerular filtration rate. This is associated with lowering of body weight and may reduce systolic blood pressure. The increased glucosuria appears to increase the risk of genital infections but may not increase the risk of urinary tract infections. SUMMARY: The ability of SGLT2 inhibitors to reduce plasma glucose without inducing increased insulin secretion, clinically relevant hypoglycemia, or weight gain constitutes a major advance. The ability to increase glucose excretion provides a powerful means to treat caloric excess conditions. Important questions remain to be resolved and more clinical research is needed on the long-term effects of SGLT2 inhibition. Potential extrarenal effects need to be explored in order to determine the safety of these compounds. It also remains to be determined whether these drugs lower the toxicity of glucose directly on renal cells, independent of hyperglycemia, which may slow or prevent the progressive nature of diabetic nephropathy.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAbsorptionBenzhydryl CompoundsDiabetes MellitusDiabetes Mellitus, Type 2Diabetic NephropathiesGlucoseGlucosidesHumansKidneySodium-Glucose Transporter 2Benzhydryl CompoundsdapagliflozinGlucoseGlucosidessergliflozinSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID20539226
PMCPMC5886710
OpenAlexW1978796367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.